Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease - Wikidata - wikimedia - TriplyDB

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease

http://www.wikidata.org/entity/Q33647691

about

The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people Mild cognitive impairment in Parkinson's disease.Cognitive Training in Parkinson's Disease: A Review of Studies from 2000 to 2014 Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study Parkinson's Disease and Cognitive Impairment A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015.Treatment of psychosis and dementia in Parkinson's disease.Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association?The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis.Targeting impulsivity in Parkinson's disease using atomoxetine Parkinson's disease: the quintessential neuropsychiatric disorder Neuropsychological outcomes after psychosocial intervention for depression in Parkinson's disease.Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.Off-label use of atomoxetine in adults: is it safe?Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis Noradrenaline and Parkinson's disease.Neurobiology of depression and anxiety in Parkinson's disease A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease Monoamine reuptake inhibitors in Parkinson's disease.Improving response inhibition in Parkinson's disease with atomoxetine.Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing.Parkinson's disease dementia: a neural networks perspective.Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications.Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease.Impulsivity and apathy in Parkinson's disease.Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis.Distant delivery of a mindfulness-based intervention for people with Parkinson's disease: the study protocol of a randomised pilot trial.Mild cognitive impairment in Parkinson's disease.Cognitive impairment in nondemented Parkinson's disease.Drug treatments for the neuropsychiatric complications of Parkinson's disease.Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.New tricks for old dogmas: optogenetic and designer receptor insights for Parkinson's disease Noradrenergic modulation of cognition: therapeutic implications.Depression in Parkinson's disease: identification and management.Cognitive deficits in Parkinson's disease: a cognitive neuroscience perspective.

P2860

Q26799352-558311DD-C80B-4D3E-89CE-16660BC45078 Q27021220-CC019337-87EE-4AE5-85B2-67792E9EC337 Q28073680-01577199-90EE-45A7-A26D-5A31DB3C447F Q28833274-48532DB7-4026-4DDE-978B-ECE113581604 Q30239814-7CE5265A-A630-4960-99BF-B6BAC2E67AF5 Q30240991-294936C1-833C-4333-B83C-D7EAE575010D Q30358337-DA1682D5-AABC-4342-B3E2-8D90AEACE39F Q31080551-7BA92DF9-450E-4D62-801D-06D4BCD49BE8 Q33607256-D11659BC-88B6-4592-B2D3-6B6B4ED52BA6 Q33765388-E2AAE5E6-A0AD-4F69-BF32-D09300403EA3 Q33784038-B5B26E9A-D9F1-4CBA-B438-D095FCB8CD47 Q33917094-EA305C2D-1091-4B29-AEF8-669A7B43251E Q34089583-6A6DD20F-B72C-4C44-BC78-3051AA4F2CC7 Q34135756-1A73DC6C-FEA7-430B-A20F-CC199D66D36B Q34307633-9A32B7CF-4A35-4B15-B525-C506A6F89FA1 Q34388686-17FB5052-2473-4204-A967-39D9F99BFE1B Q34618993-13B016FA-B0F1-4411-8199-75EF89E7807E Q35009609-692EEE2D-6926-4B2C-9F02-0C81E3B5A351 Q35013240-3BB43047-25D6-42A6-8FA2-44D6D3B0263B Q35028706-0E5AD1A8-543D-4E97-8DD0-D762ECEF4231 Q35043846-1BB5CF32-3D97-4DB6-845B-4002C0DA8A80 Q35165280-730B06DB-F3B9-4C16-8B0A-DB91B2DC6EB7 Q35264006-4EAD6EE1-372F-4F3D-B9E5-931C05D4E3E6 Q35276597-B07A0506-8364-45A4-9DBD-D5C6A1378A11 Q35614156-DB987B8E-A6EF-4F84-9037-2B456C6F41CC Q36010298-572C92A4-DCCE-4A20-975B-91778FEC8326 Q36186763-B9409184-AA64-432B-A805-21289D2572CE Q36351543-ACF02248-AA3A-479E-8583-86F72E668FE9 Q36998284-FA7B53A1-7D85-4832-8715-5FFC1231A5E5 Q37331607-22889268-9CA8-4B6A-A542-F4474184227E Q37364568-3D6B95EF-8C41-456A-95ED-9D8695604A0A Q37593613-59F6C5E3-818E-43D1-A928-2DCA409D704B Q37864573-5033B965-55A8-4F67-A06D-767E474FC35F Q37968511-1FC6744C-5974-4A72-B267-726BE49D3910 Q38067142-CF129815-B066-4F20-95F1-7B5617A5C63A Q38070888-956CE11A-77C2-4583-B899-F290A852267E Q38075712-05D4EB09-431D-4378-BD7A-263252DF7025 Q38091914-963A4DE3-4DF1-43DC-85CB-31E9830D6C2A Q38116807-204AA02D-4C1F-49A0-B711-C0473B4CCC3E Q38206496-9F4B746C-A8C9-4426-A731-1B72B1FFE6E1

P2860

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease

http://www.wikidata.org/entity/Q33647691

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease

@ast

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease

@en

type

label

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease

@ast

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease

@en

prefLabel

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease

@ast

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease

@en

P1433

Q33647691-B6917035-356F-4937-B5B6-41140CC62627

P1476

Q33647691-22C93510-D7CD-4144-B704-57119D6CC31D

P2093

Q33647691-1E89BF2E-22D3-4774-BC99-FBBFDF1264C2

Q33647691-21C82DF5-2E4B-472F-B376-C70BAEDA19AD

Q33647691-3850F02E-F199-4C77-979D-5E852BBF2EFD

Q33647691-39ACF398-246E-4B76-A616-8F37D45C9E01

Q33647691-59055484-500C-41B0-8B01-A299AEA947BC

Q33647691-5F7A652A-0F1D-4E6E-ABC6-72B5E511C3C3

Q33647691-71694C66-94CE-4505-81DD-2DF7B561D7AA

Q33647691-8C96BF55-FDEF-4D77-87E5-A46A4A9925A9

Q33647691-AB3F8D13-5910-4E41-8F64-E11434D9D1C9

Q33647691-AB8774EC-6E14-4CB4-9251-04A897176201

P2860

Q33647691-00BAF89C-6601-4328-8781-DC09F23B5FD9

Q33647691-08A1C809-D6B3-4377-AAD4-EBC174DC27A7

Q33647691-174F32C1-4AC9-4D0F-ACA3-155F7EA579D2

Q33647691-241C2928-D61A-4965-80FF-8EFF00603EA6

Q33647691-28FBEDB0-4651-490C-81A8-EB46EDAC1DDC

Q33647691-376C0580-0B76-4166-8E8A-35C56CA51B48

Q33647691-425A225D-10B8-4192-B7D1-71F8764AD7E0

Q33647691-46C02FCB-8578-47E0-9C63-98B470872045

Q33647691-5A18A1DC-8497-48EA-B2BF-76BEB54655A4

Q33647691-5EA598FB-E641-4C36-A2E6-6018BC3232D5

P304

Q33647691-6108DC01-E7DB-44BE-94F4-2B324D46D8D9

P31

Q33647691-3313D0D7-DB47-463D-B3B1-993AA880C95E

P356

Q33647691-9366FDB7-FF8E-4393-AC84-5E1DC0C2FE8B

P407

Q33647691-1E72B0DC-0E86-47A5-9E37-AC2728A59FB3

P433

Q33647691-EF1F0C98-EF38-4776-9C49-18DC5778492D

P478

Q33647691-FBAD7283-DC14-4001-87DF-1C2962C26385

P577

Q33647691-8D6D628F-F9E4-4D87-BE1D-1B473A111539

P698

Q33647691-8AB3798D-5600-4FB0-A070-B864A597CA8E

P921

Q33647691-813F6DBE-53C1-40B8-B8E6-FB3123D5F96B

P932

Q33647691-9E29A34C-60B0-4B62-9A04-C1E574F003F1

P356

WNL.0B013E3181EBDD79

P1433

P1476

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease

@en

P2093

A Colcher

http://www.w3.org/2001/XMLSchema#string

A D Siderowf

http://www.w3.org/2001/XMLSchema#string

D Weintraub

http://www.w3.org/2001/XMLSchema#string

E Mamikonyan

http://www.w3.org/2001/XMLSchema#string

H I Hurtig

http://www.w3.org/2001/XMLSchema#string

J E Duda

http://www.w3.org/2001/XMLSchema#string

M B Stern

http://www.w3.org/2001/XMLSchema#string

S Mavandadi

http://www.w3.org/2001/XMLSchema#string

S Nazem

http://www.w3.org/2001/XMLSchema#string

S S Horn

http://www.w3.org/2001/XMLSchema#string

P2860

Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans

“Mini-mental state”

A new method for measuring daytime sleepiness: the Epworth sleepiness scale

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease

Provisional diagnostic criteria for depression of Alzheimer disease.

Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants.

Diagnostic criteria for Parkinson disease.

What contributes to quality of life in patients with Parkinson's disease?

Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.

P304

448-455

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0B013E3181EBDD79

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

75

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20679638

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

2918470

http://www.w3.org/2001/XMLSchema#string